Mga Batayang Estadistika
| LEI | 549300D3W3Q8CN30YO25 |
| CIK | 1837412 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CM Life Sciences II Inc - Class A
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| January 29, 2024 |
SLGC / Standard BioTools Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d33sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* SomaLogic, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 83444K105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-40090 SOMALOGIC, INC. (Exact name of Registrant as specified in its charter |
|
| January 9, 2024 |
SLGC / Standard BioTools Inc. / CMLS Holdings II LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration No. |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration No. |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration No. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 SomaLogic, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40090 85-4298912 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration No. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 5, 2024 |
As filed with the Securities and Exchange Commission on January 5, 2024 As filed with the Securities and Exchange Commission on January 5, 2024 Registration No. |
|
| January 4, 2024 |
DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 2, 2024 |
Exhibit 99.1 SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting “FOR” Pending Merger with Standard BioTools Leading Independent Proxy Advisory Firms ISS and Glass Lewis Both Recommend SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools BOULDER, Colo., January 2, 2024 – SomaLogic, Inc. (Nasdaq: SLGC) (“the Company”), a leader in proteomics technology, |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| December 29, 2023 |
Exhibit 99.1 SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders Continues to Recommend Stockholders Vote “FOR” Pending Merger ISS has Dismissed Madryn’s Misleading Claims and Reaffirms that Stockholders Vote “FOR” the Merger BOULDER, Colo., Dec. 29, 2023 – SomaLogic, Inc. (Nasdaq: SLGC) (“the Company”), a leader in proteomics tec |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 29, 2023 |
Exhibit 99.1 Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 29, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| December 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| December 29, 2023 |
Exhibit 99.1 Leading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools Glass Lewis Recommendation Emphasizes Strong Strategic Rationale and Thorough Process ISS Reiterates Recommendation Following Public Commentary Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockh |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 26, 2023 |
Exhibit 99.1 ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif. - December 22, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 26, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SomaLogic Issues Statement Correcting Madryn Asset Management’s Misleading Disclosure SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic’s Thorough Strategic Process Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders BOULDER, Colo., Dec. |
|
| December 26, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SomaLogic Issues Statement Correcting Madryn Asset Management’s Misleading Disclosure SomaLogic Publishes Key Correspondence from LabCorp CEO Omitted by Madryn in its Attempt to Undermine Confidence in SomaLogic’s Thorough Strategic Process Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders BOULDER, Colo., Dec. |
|
| December 26, 2023 |
Exhibit 99.1 ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting BOULDER, Colo. - December 22, 2023 – SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services (“ISS”) has recommended that SomaLogic stockholders vote |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 26, 2023 |
Exhibit 99.1 ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioTools Company Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting BOULDER, Colo. - December 22, 2023 – SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services (“ISS”) has recommended that SomaLogic stockholders vote |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 26, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 21, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn’s Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| December 19, 2023 |
Exhibit 99.3 Dear First Last Name: Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Plan of Merger with SomaLogic, Inc. and the Merger cannot be consummated unless the stockholders of Standard BioTools, Inc. appro |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| December 19, 2023 |
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Exhibit 99.1 Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Legal Information 3 (1) Assumes transaction close in Q1 2024. Total cost synergies exclude non - cash, restructuring - related and other non - recurring costs for each of Standard BioTools and SomaLogic. (2) Based on assumed Q1 2024 close and estimated combined cash balance of Standard BioTools and SomaLogic, le |
|
| December 19, 2023 |
Exhibit 99.2 Hi {fname}! This is {agentfirstname} with Alliance Advisors, on behalf of your investment with Standard BioTools, Inc., and the Board of Directors. Standard BioTools Inc.’s Special Meeting of Stockholder is fast approaching, and according to our records we have not received your vote. As previously announced by The Company, Standard BioTools Inc. have entered into an Agreement and Pla |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No . ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| December 12, 2023 |
PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION DATED DECEMBER 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commissio |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| December 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., December 4, 2023 - Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commission |
|
| December 1, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| November 29, 2023 |
Exhibit 99.1 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, ma |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Standard BioTools Inc. (Exact name of registrant as specified in its charter) Delaware 001-34180 77-0513190 (State or other jurisdiction of incorporation) (Commissio |
|
| November 29, 2023 |
Exhibit 99.1 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, ma |
|
| November 29, 2023 |
Exhibit 99.1 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, ma |
|
| November 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40090 SOMALOGIC, |
|
| November 8, 2023 |
Filed by Standard BioTools Inc. Filed by Standard BioTools Inc. Commission File No.: 001-34180 Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 On November 7, 2023, Standard BioTools Inc. (“Standard BioTools”) issued a press release reporting its financia |
|
| November 8, 2023 |
CONFIDENTIAL AMENDMENT NO. 3 TO COLLABORATION AGREEMENT This Amendment No. 3 to Collaboration Agreement (the "Amendment") effective as of date of last signature below (the "Amendment Effective Date") by and among lllumina Cambridge, Ltd., a private company limited by shares organized under the laws of England and Wales, with an address at lllumina Centre, 19 Granta Park, Great Abington, Cambridge, |
|
| November 8, 2023 |
SomaLogic Reports Recent Business Highlights and Third Quarter 2023 Financial Results Exhibit 99.1 SomaLogic Reports Recent Business Highlights and Third Quarter 2023 Financial Results - Revenue of $22.0 million, reflecting 14% year-over-year growth when excluding royalty revenue from NEB in the corresponding prior-year period - Cash and investments of over $450 million - Raising full year 2023 revenue guidance to $82 million to $85 million - Management to host conference call toda |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commissio |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 4, 2023 |
Exhibit 99.3 Execution Version VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedu |
|
| October 4, 2023 |
Exhibit 99.5 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation (the “Company”), Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Filed by SomaLogic, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 Operator: Good morning and welcome to today’s Standard BioTools and SomaLogic merger announcement conference call. Before market open today, Standard |
|
| October 4, 2023 |
SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice Exhibit 10.1 SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice To: Date: SomaLogic, Inc., a Delaware corporation (the “Company”) is being acquired by Standard BioTools Inc., a Delaware corporation (the “Parent”), pursuant to the Agreement and Plan of Merger (as may be amended from time to time in accordance with its terms, the “Merger Agreement”), by and among t |
|
| October 4, 2023 |
Exhibit 99.2 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools O C T O B E R 4 , 2 0 2 3 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements |
|
| October 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach |
|
| October 4, 2023 |
Exhibit 99.5 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among SomaLogic, Inc., a Delaware corporation (the “Company”), Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Filed by SomaLogic, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 Dear SomaLogic Colleagues, This morning, we announced our intent to merge with Standard BioTools, (NASDAQ: LAB), a company that shares our mission to |
|
| October 4, 2023 |
SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice Exhibit 10.1 SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice To: Date: SomaLogic, Inc., a Delaware corporation (the “Company”) is being acquired by Standard BioTools Inc., a Delaware corporation (the “Parent”), pursuant to the Agreement and Plan of Merger (as may be amended from time to time in accordance with its terms, the “Merger Agreement”), by and among t |
|
| October 4, 2023 |
Exhibit 99.4 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Exhibit 99.4 VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signa |
|
| October 4, 2023 |
Exhibit 99.3 Execution Version VOTING AGREEMENT This Voting Agreement (this “Agreement”), dated as of October 4, 2023, is by and among Standard BioTools Inc., a Delaware corporation (“Parent”), Martis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), SomaLogic, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedu |
|
| October 4, 2023 |
Exhibit 99.1 Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools’ strategy to unlock value in underserved portion of $100 billion industry Establishes leading platform of multi-omic technologies with the highest throughput and highest data quality to power clinical research insights Expands commercial reach |
|
| October 4, 2023 |
Exhibit 99.2 Standard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools O C T O B E R 4 , 2 0 2 3 Legal Information Forward-looking statements This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 4, 2023 |
Filed by SomaLogic, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 Who is Somalogic? “SomaLogic (Nasdaq: SLGC) is fostering the discovery of effective and safer treatments for patients in need while empowering more a |
|
| October 4, 2023 |
Filed by SomaLogic, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: SomaLogic, Inc. Commission File No.: 001-40090 Dear Valued Customer, I am writing to share the news that SomaLogic has entered into a definitive agreement to merge with Standard BioTools Inc., a co |
|
| October 4, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC. Dated as of October 4, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER; CLOSING; SURVIVING COMPANY 2 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 The Certificate of Incorporation 2 1.5 The Bylaws 3 1.6 Directors and Officers of Parent 3 1.7 Directors and Officers of the S |
|
| October 4, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., STANDARD BIOTOOLS INC., and MARTIS MERGER SUB, INC. Dated as of October 4, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGER; CLOSING; SURVIVING COMPANY 2 1.1 The Merger 2 1.2 Closing 2 1.3 Effective Time 2 1.4 The Certificate of Incorporation 2 1.5 The Bylaws 3 1.6 Directors and Officers of Parent 3 1.7 Directors and Officers of the S |
|
| August 14, 2023 |
SomaLogic Reports Second Quarter 2023 Financial Results Exhibit 99.1 SomaLogic Reports Second Quarter 2023 Financial Results - Revenue of $20.5 million, an increase of 45% year-over-year - Cash and investments of approximately $474 million, a strong capital position to fund current and future business initiatives - Reiterating full year 2023 revenue guidance and operating expense target - Management to host conference call today at 4:30pm ET BOULDER, C |
|
| August 14, 2023 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of June [], 2023 (the “Effective Date”), by and between SomaLogic Operating Co., Inc., a Delaware corporation, with its principal place of business being 2945 Wilderness Place, Boulder, CO 80301 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal |
|
| August 14, 2023 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE Execution Version Exhibit 10.3 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (“Agreement”) is entered into between Shaun Blakeman (“Employee”) and SomaLogic, Inc. (“the Company”), collectively referred to as the “Parties.” Reference is made herein to that certain Key Employee Severance Plan adopted by the Company on October 17, 202 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40090 SOMALOGIC, INC. |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2023 |
CONFIDENTIAL Exhibit 10.1 SECOND AMENDMENT TO LSG MICROARRAY SUPPLY AGREEMENT This Second Amendment to LSG Microarray Supply Agreement (“Second Amendment”), effective as of the date of the last signature below (the “Amendment Date”), is by and between Agilent Technologies, Inc. (“Agilent”) and SomaLogic Operating Co., Inc. (“Customer”) (collectively, the “Parties”) and is intended to amend certain |
|
| June 22, 2023 |
Exhibit 10.1 CONFIDENTIAL SECOND AMENDMENT TO COLLABORATION AGREEMENT H1 and H2 Probes This Second Amendment to Collaboration Agreement (the “Amendment”) effective as of date of last signature below (the “Amendment Effective Date”) by and among Illumina Cambridge, Ltd., a private company limited by shares organized under the laws of England and Wales, with an address at Illumina Centre, 19 Granta |
|
| June 22, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission F |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorpora |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 6, 2023 |
Exhibit 99.1 SomaLogic Announces Chief Financial Officer Transition Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 6, 2023 (GLOBE NEWSWIRE) - SomaLogic, Inc. (Nasdaq: SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO whi |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40090 SOMALOGIC, INC |
|
| May 15, 2023 |
SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice Exhibit 10.2 SOMALOGIC, INC. Key Employee Severance Plan Amended and Restated Participation Notice To: Roy Smythe Date: March 28, 2023 SomaLogic, Inc. (the “Company”) has adopted the SomaLogic, Inc. Key Employee Severance Plan (the “Plan”). The Company is providing you this Amended and Restated Participation Notice (this “Participation Notice”) to inform you that you have been designated as a Part |
|
| May 15, 2023 |
Exhibit 10.3 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Arbeitsvertrag / Employment Agreement zwischen / between Velocity Global GmbH (***) (“Arbeitgeber/Verleiher” / “Employer/Lender”) und / and Pi Zheng (***) (“Arbeitnehmer” / “ |
|
| May 15, 2023 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (“Agreement”) is entered into between Roy Smythe (“Employee”) and SomaLogic, Inc. (“the Company”), collectively referred to as the “Parties.” Reference is made herein to that certain Key Employee Severance Plan adopted by the Company on October 17, 2022 (the “Plan”), under |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
SomaLogic Reports First Quarter 2023 Financial Results Exhibit 99.1 SomaLogic Reports First Quarter 2023 Financial Results –First quarter 2023 revenue of $20.4 million, representing a decrease of 11% year-over-year; excluding licensing, revenue increased 2% year-over-year. –Reiterating full year 2023 revenue guidance of $80-84 million –Expense reduction initiatives on track and maintaining full year 2023 operating expense targets –Cash and investments |
|
| May 4, 2023 |
PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Statement No. 333 259954 48,413,333 Shares of Common Stock 5,013,333 Warrants to Purchase Shares of Common Stock 10,533,333 Shares of Common Stock Underlying Warrants 838,100 Shares of Common Stock Underlying Options This prospectus relates to the offer and sale from time to time by the Selling Securityholders named in this prospectus (the “ |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 1, 2023 |
April 28, 2023 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: SomaLogic, Inc. Request for Withdrawal of Post-Effective Amendment No. 4 to Form S-1 Filed March 29, 2023 (SEC Accession No. 23771555/Commission File No. 333-259954) Dear Sir or Madam: On March 29, 2023, SomaLogic, Inc. (the “Company”) filed Post-Effective Amendment No. 4 to Form |
|
| April 25, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorpo |
|
| April 14, 2023 |
As filed with the Securities and Exchange Commission on April 14, 2023 POS AM 1 ea176885-posama5somalogic.htm POST-EFFECTIVE AMENDMENT NO. 5 TO FORM S-1 As filed with the Securities and Exchange Commission on April 14, 2023 Registration No. 333-259954 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 5 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 SOMALOGIC, INC. (Exact name of Regis |
|
| April 3, 2023 |
Retention Agreement, dated March 28, 2023, between SomaLogic Operating Co., Inc. and Shaun Blakeman Exhibit 10.1 March 16, 2023 Shaun Blakeman Re: Retention Agreement Dear Shaun, As a valued employee of SomaLogic Operating Co., Inc. or its affiliates (collectively, “SomaLogic”), SomaLogic views your continued service and expertise as vital to the success of our company. Therefore, in exchange for your continued employment with SomaLogic, we are pleased to offer you a one-time retention bonus (“B |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| March 29, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 29, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 259954 Prospectus Supplement No. 3 (To Prospectus dated October 24, 2022) This prospectus supplement updates, amends and supplements the prospectus dated October 24, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259954). Capitalized terms used in this Prospectus Supplement and not o |
|
| March 29, 2023 |
The date of this prospectus supplement is March 28, 2023 Filed Pursuant to Rule 424(b)(3) Registration No. 333- 259954 Prospectus Supplement No. 2 (To Prospectus dated October 24, 2022) This prospectus supplement updates, amends and supplements the prospectus dated October 24, 2022 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259954). Capitalized terms used in this Prospectus Supplement and not o |
|
| March 28, 2023 |
Employment Letter, dated March 24, 2023, between SomaLogic, Inc. and Adam Taich EX-10.1 2 ea175852ex10-1somalogic.htm EMPLOYMENT LETTER, DATED MARCH 24, 2023, BETWEEN SOMALOGIC, INC. AND ADAM TAICH Exhibit 10.1 March 24, 2023 Adam Taich Dear Adam: We are pleased to appoint you to the position of Interim Chief Executive Officer. Your official transition date is 03/28/2023. Compensation: Your compensation package is as follows: a) Salary: Your annual salary will be $600,000 pai |
|
| March 28, 2023 |
Calculation of Filing Fees Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) SomaLogic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 pa |
|
| March 28, 2023 |
Exhibit 21.1 SUBSIDIARIES OF SOMALOGIC, INC. Name of Subsidiary Jurisdiction SomaLogic Operating Co., Inc. Delaware SomaLogic Limited United Kingdom Panther Merger Subsidiary II, LLC Delaware SomaLogic Singapore PTE. LTD. Singapore |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 28, 2023 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
EX-99.1 3 ea175852ex99-1somalogic.htm PRESS RELEASE DATED MARCH 28, 2023 Exhibit 99.1 SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results Announces Director Appointments and Management Evolution ● Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational execution ● Board transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hib |
|
| March 28, 2023 |
EX-10.38 2 a2022q4exhibit1038.htm EX-10.38 Exhibit 10.38 CONFIDENTIAL EXECUTION COPY FIRST AMENDMENT TO COLLABORATION AGREEMENT Catch0 Manufacturing Evaluation This First Amendment to Collaboration Agreement (the “Amendment”) effective as of date of last signature below (the “Amendment Effective Date”) by and among Illumina Cambridge, Ltd., a private company limited by shares organized under the l |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2023 |
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2023 |
Employment Agreement, dated October 18, 2022, between Velocity Global GmbH and Pi Zheng Exhibit 10.1 Arbeitsvertrag / Employment Agreement zwischen / between Velocity Global GmbH Prielmayerstr. 3 c/o Rüter und Partner Steuerberatungsgesellschaft 80335 München (“Arbeitgeber/Verleiher” / “Employer/Lender”) und / and Pi Zheng Sybelstr 31 Berlin 10629 (“Arbeitnehmer” / “Employee”) (gemeinsam auch “die Parteien” genannt / jointly referred to as “the Parties”) DEUTSCHE FASSUNG ENGLISH VERS |
|
| March 9, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE SOMALOGIC, INC. ) C.A. No. 2023-0175-LWW ) [PROPOSED] FINAL ORDER AND JUDGMENT WHEREAS, this Court having reviewed the Verified Petition for Relief Pursuant to 8 Del. C. § 205 (the “Petition”) filed by petitioner SomaLogic, Inc., the Court having considered the factors in 8 Del. C. § 205(d), and for good cause having been |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission F |
|
| February 17, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| February 17, 2023 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE SOMALOGIC, INC. ) ) c.a. no. 2023- verified petition for relief pursuant to 8 del. c. § 205 Petitioner SomaLogic, Inc. (“SomaLogic” or the “Company”), by and through its undersigned counsel, brings this petition pursuant to 8 Del. C. § 205, seeking to have this Court validate a potentially defective corporate act as follows: natu |
|
| February 14, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2023 |
SLGC / SomaLogic Inc - Class A / Gold Lawrence Marshall - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 eh23032991813ga1-somalogic.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) SomaLogic, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 83444K105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Sta |
|
| January 10, 2023 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Amendment #2 to Master Collaboration Agreement Reference is hereby made to the Master Collaboration Agreement (the “Agreement”), dated September 2 |
|
| January 10, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
EX-99.1 2 ea171392ex99-1somalogic.htm PRESS RELEASE ISSUED BY SOMALOGIC, INC. ON JANUARY 9, 2023 Exhibit 99.1 SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific Time BOULDER, Colo., January 9, 2023 (GLOBE NEWSWIRE) - SomaLogic, I |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SomaLogic, Inc. (Name of Issuer) CMLS Holdings II LLC Eli Casdin and Keith Meister c/o Corvex Management LP 667 Madison Avenue New York, New York 10065 (212) 474-6745 (Name, Address and Telephone Number of Person Authorized to Receive Notice and Communic |
|
| November 18, 2022 |
9,608,860 Shares of Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-268066 9,608,860 Shares of Common Stock This prospectus relates to the offer and sale from time to time by the Selling Stockholders named in this prospectus (the ?Selling Stockholders?) of up to 9,608,860 shares of our common stock, par value $0.0001 per share (?Common Stock?), consisting of (i) 4,030,472 shares of our Comm |
|
| November 17, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-259954 Prospectus Supplement No. 1 (To Prospectus dated October 24, 2022) This prospectus supplement updates, amends and supplements the prospectus dated October 24, 2022 (as supplemented, the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259954). Capitalized terms used in this Prospectus Supp |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-40090 SOMALOGIC, |
|
| November 15, 2022 |
November 15, 2022 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: SomaLogic, Inc. Registration Statement on Form S-3 Filed October 31, 2022 Commission File No. 333-268066 Dear Sir or Madam: Pursuant to Rule 461 under the Securities Act of 1933, as amended, SomaLogic, Inc. (the ?Company?) hereby requests that the effective date of the above-ca |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2022 |
SomaLogic Reports Third Quarter 2022 Financial Results Exhibit 99.1 SomaLogic Reports Third Quarter 2022 Financial Results ?Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million. ?Core life science revenue of $20.5 million, representing an increase of 2.9% year-over-year and 45.4% compared to the last quarter. ?On track to reduce operational expenses by $75 million through 2023. ?Raising 2022 full year revenue gui |
|
| October 31, 2022 |
As filed with the Securities and Exchange Commission on October 28, 2022 S-3 1 ea167649-s3somalogic.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on October 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 SOMALOGIC, INC. (Exact name of Registrant as specified in its charter) Delaware 85-4298912 (State or other jurisdi |
|
| October 31, 2022 |
Calculation of Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) SomaLogic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward F |
|
| October 24, 2022 |
424B3 1 ea167399-424b3somalogic.htm PROSPECTUS PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259954 48,413,333 Shares of Common Stock 5,013,333 Warrants to Purchase Shares of Common Stock 10,533,333 Shares of Common Stock Underlying Warrants 838,100 Shares of Common Stock Underlying Options This prospectus relates to the offer and sale from time to time by the Selling |
|
| October 18, 2022 |
Key Employee Severance Plan, dated October 17, 2022. Exhibit 10.2 EXECUTION VERSION SOMALOGIC, INC. KEY EMPLOYEE SEVERANCE PLAN 1. Introduction. This Key Employee Severance Plan (the ?Plan?) is established by SomaLogic, Inc. (the ?Company?) effective as of October 17, 2022 (the ?Effective Date?) to provide severance benefits to selected employees of the Company. This document constitutes the Summary Plan Description for the Plan. 2. Definitions. For |
|
| October 18, 2022 |
Employment Agreement, dated October 17, 2022, between SomaLogic, Inc. and Troy Cox. Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into as of October 17, 2022 (the ?Effective Date?), between Troy Cox (the ?Employee?), and SomaLogic, Inc. (the ?Company?). RECITALS A. The Employee is currently a member of the Company?s Board of Directors. The Company now wishes to employ the Employee on a part-time basis as the Company?s Executive Chairman |
|
| October 18, 2022 |
Exhibit 99.1 SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors BOULDER, Colo., SAN DIEGO, Ca.? SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company?s Board of Directors. The current Chair, Chuck L |
|
| October 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 85-4298912 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 17, 2022 |
CORRESP 1 filename1.htm October 17, 2022 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: SomaLogic, Inc. Post-Effective Amendment No. 3 to Registration Statement on Form S-1 Filed September 23, 2022 Commission File No. 333-259954 Dear Sir or Madam: Pursuant to Rule 461 under the Securities Act of 1933, as amended, SomaLogic, Inc. (the “Compan |
|
| October 17, 2022 |
October 17, 2022 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: SomaLogic, Inc. Post-Effective Amendment No. 3 to Registration Statement on Form S-1 Filed September 23, 2022 Commission File No. 333-259954 Dear Sir or Madam: Reference is made to our letter, filed as correspondence via EDGAR on October 13, 2022, in which we requested the accel |
|
| October 13, 2022 |
October 13, 2022 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: SomaLogic, Inc. Post-Effective Amendment No. 3 to Registration Statement on Form S-1 Filed September 23, 2022 Commission File No. 333-259954 Dear Sir or Madam: Pursuant to Rule 461 under the Securities Act of 1933, as amended, SomaLogic, Inc. (the “Company”) hereby requests that |
|
| September 26, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022 As filed with the Securities and Exchange Commission on September 23, 2022 Registration No. |
|
| September 26, 2022 |
Calculation of Filing Fees Table. Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) SomaLogic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security?Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 pa |
|
| September 26, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022 S-8 POS 1 ea166199-s8possomalogic.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 As filed with the Securities and Exchange Commission on September 23, 2022 Registration No. 333-260892 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SomaLogic, Inc. (Exact name of registrant as sp |
|
| September 23, 2022 |
As filed with the Securities and Exchange Commission on September 23, 2022 As filed with the Securities and Exchange Commission on September 23, 2022 Registration No. |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 15, 2022 |
SomaLogic Reports Second Quarter 2022 Financial Results Exhibit 99.1 SomaLogic Reports Second Quarter 2022 Financial Results ?Second quarter 2022 revenue of $14.1 million, bringing year to date revenue to $37.1 million. ?Reducing 2022 revenue guidance to $80-90 million to account for ongoing variability in core service business, macroeconomic and commercial factors. ?Maintaining substantial cash, cash equivalents, and current investments of $619.1 mill |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, INC. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| July 27, 2022 |
SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan Exhibit 99.1 FOR IMMEDIATE RELEASE SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan? Assay ? Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic?s platform while expanding footprint to San Diego, CA BOULDER, Colo. and SAN DIEGO, Calif. (July 26, 2022) ? SomaLogic (N |
|
| July 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 27, 2022 |
Exhibit 2.1 CERTAIN INFORMATION IDENTIFIED WITH THE MARK ?[***]?, ?[***%***]? AND ?[***$***]? HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. AGREEMENT AND PLAN OF MERGER among SOMALOGIC, INC., PANTHER MERGER SUBSIDIARY I, LLC, PANTHER MERGER SUBSIDIARY II, LLC, PALAMEDRIX, I |
|
| July 22, 2022 |
As filed with the Securities and Exchange Commission on July 22, 2022 As filed with the Securities and Exchange Commission on July 22, 2022 Registration No. |
|
| July 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission F |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 20, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-259954 Prospectus Supplement No. 1 (To Prospectus dated October 15, 2021) This prospectus supplement updates, amends and supplements the prospectus dated October 15, 2021, as supplemented to date (as supplemented, the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259954). Capitalized terms use |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, INC |
|
| May 12, 2022 |
Exhibit 99.1 SomaLogic Reports First Quarter 2022 Financial Results Company to host conference call today at 4:30 p.m. ET BOULDER, Colo. (May 12, 2022) ? SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended March 31, 2022. ?Our successful first quarter has kickstarted another exciting year for SomaLogic as we continue to apply th |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2022 |
As filed with the Securities and Exchange Commission on May 11, 2022 As filed with the Securities and Exchange Commission on May 11, 2022 Registration No. |
|
| May 11, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-259954 Prospectus Supplement No. 1 (To Prospectus dated October 15, 2021) This prospectus supplement updates, amends and supplements the prospectus dated October 15, 2021 (the ?Prospectus?), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-259954). Capitalized terms used in this Prospectus Supplement and not ot |
|
| April 25, 2022 |
DEF 14A 1 d313269ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| March 29, 2022 |
Exhibit 10.35 CERTAIN INFORMATION IDENTIFIED WITH THE MARK ?(***)?, ?(***%***)? AND ?(***$***)? HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL CATALOG PRODUCT SUPPLY AGREEMENT- OEM RESALE (GE Healthcare Life Sciences Catalog Product) 1. GEHC GE Healthcare Bio-Sciences Corp. 100 Results W |
|
| March 29, 2022 |
Exhibit 10.34 CERTAIN INFORMATION IDENTIFIED WITH THE MARK ?(***)?, ?(***%***)? AND ?(***$***)? HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. LSG MICROARRAY SUPPLY AGREEMENT AGREEMENT NO. AHD71 THIS LSG MICROARRAY SUPPLY AGREEMENT (?Agreement?) is entered into as of April 8, 2019 (the ? |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| March 29, 2022 |
SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results ?Fourth quarter 2021 revenue of $23.0 million contributed to record full year revenue of $81.6 million, 46% growth over the prior year ?Established over 75 new customer accounts, expanding and diversifying revenue base ?Substantial cash and investments of $657.7 million at year-end ?Maintaining 2022 full year revenu |
|
| March 29, 2022 |
Exhibit 21.1 SUBSIDIARIES OF SOMALOGIC, INC. Name of Subsidiary Jurisdiction SomaLogic Operating Co., Inc. Delaware SomaLogic Limited United Kingdom |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission |
|
| March 29, 2022 |
EX-10.36 5 a2021q4ex1036illuminaagree.htm EX-10.36 Exhibit 10.36 AGREED FORM CONFIDENTIAL CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT AND FILED SEPARATELY WITH THE SEC PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST WITH RESPECT TO THIS OMITTED INFORMATION. COLLABORATION AGREEMENT by and among Illumina Cambridge, Ltd., Illumina |
|
| March 29, 2022 |
Description of Company’s Securities Exhibit 4.3 DESCRIPTION OF SECURITIES The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities. The full text of our Second Amended and Restated Certificate of Incorporation (the ?Amended and Restated Certificate of Incorporation?) is attached as an exhibit to Form 8-K filed on September 8, 2021. We urge |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| February 16, 2022 |
Exhibit 10.1 STANDARD LEASE AGREEMENT FOR OFFICE/WAREHOUSE SPACE THIS LEASE AGREEMENT (hereafter called the ?Lease Agreement?) made as of the 10th day of February, 2022, by and between LOUISVILLE 1 INDUSTRIAL OWNER, LLC, a Delaware limited liability company (hereafter called the ?Landlord?) and SOMALOGIC OPERATING CO., INC., a Delaware corporation (hereafter called the ?Tenant?). ARTICLE 1. DESCRI |
|
| February 16, 2022 |
EXHIBIT 10.2 STANDARD LEASE AGREEMENT FOR OFFICE/WAREHOUSE SPACE THIS LEASE AGREEMENT (hereafter called the ?Lease Agreement?) made as of the 10th day of February, 2022, by and between LOUISVILLE 2 INDUSTRIAL OWNER, LLC, a Delaware limited liability company (hereafter called the ?Landlord?) and SOMALOGIC Operating Co., INC., a Delaware corporation (hereafter called the ?Tenant?). ARTICLE 1. DESCRI |
|
| February 11, 2022 |
SLGC / SomaLogic Inc - Class A / Gold Lawrence Marshall - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) SomaLogic, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 83444K105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 4, 2022 |
SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting Exhibit 99.1 SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting BOULDER, Colo., February 4, 2022 (GLOBE NEWSWIRE) ? SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th, 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time. The event is intended to highlight recent cor |
|
| February 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissio |
|
| January 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissio |
|
| January 11, 2022 |
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range Exhibit 99.1 SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range Presenting at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 a.m. Eastern Time. BOULDER, Colo., January 11, 2022 (GLOBE NEWSWIRE) ? SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced preliminary, unaudited revenue expectations for the |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| January 5, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutions Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms BOULDER, Colo. (January 5, 2022) ? SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaborati |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number 001-39796 SOMALOGIC, |
|
| November 15, 2021 |
Exhibit 99.2 Harnessing the Power of Proteomics LEADING AI - DATA DRIVEN PROTEIN PLATFORM Global commercial and technological leader for bio - pharma and clinical protein discovery, measurement and interpretation November 2021 Forward Looking Statements ? 2021 SOMALOGIC, INC. ALL RIGHTS RESERVED. PROPRIETARY AND CONFIDENTIAL. 2 Certain information, particularly relating to the future of Somalogic |
|
| November 15, 2021 |
SomaLogic Reports Third Quarter 2021 Financial Results Exhibit 99.1 SomaLogic Reports Third Quarter 2021 Financial Results ? Increase of 40% in third quarter revenue to $20.0 million over the corresponding period in 2020 ? Increase of 112% in year-to-date revenue to $58.6 million over the corresponding period in 2020 ? Raising 2021 full year revenue guidance to $77-79 million ? Addition of 61 new customer accounts expands and diversifies customer base |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 8, 2021 As filed with the Securities and Exchange Commission on November 8, 2021 Registration No. |
|
| October 18, 2021 |
424B3 1 f424b32021somalogicinc.htm PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration Statement No. 333-259954 PROSPECTUS 48,413,333 Shares of Common Stock 5,013,333 Warrants to Purchase Shares of Common Stock 10,533,333 Shares of Common Stock Underlying Warrants 838,100 Shares of Common Stock Underlying Options This prospectus relates to the offer and sale from time to time by the Selling S |
|
| October 13, 2021 |
SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 CORRESP 1 filename1.htm SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 October 13, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Cara Wirth Re: SomaLogic, Inc. – Registration Statement on Form S-1 (File No. 333-259954) Ladies and Gentlemen: SomaLogic, Inc. (the “Company”) hereby requests th |
|
| October 12, 2021 |
SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 October 12, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Cara Wirth Re: SomaLogic, Inc. – Registration Statement on Form S-1 (File No. 333-259954) Ladies and Gentlemen: Reference is made to that certain letter filed as correspondence by SomaLo |
|
| October 8, 2021 |
EXHIBIT 2 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0. |
|
| October 8, 2021 |
EVIDENCE OF SIGNATORY AUTHORITY EXHIBIT 1 EVIDENCE OF SIGNATORY AUTHORITY Excerpt from Commercial Register of Novartis Pharma AG Identification number Legal status Entry Cancelled Carried CH-270. |
|
| October 8, 2021 |
SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 SomaLogic, Inc. 2945 Wilderness Place Boulder, Colorado 80301 October 8, 2021 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Cara Wirth Re: SomaLogic, Inc. ? Registration Statement on Form S-1 (File No. 333-259954) Ladies and Gentlemen: SomaLogic, Inc. (the ?Company?) hereby requests that the U.S. Securities an |
|
| October 8, 2021 |
As filed with the Securities and Exchange Commission on October 8, 2021 Registration No. |
|
| October 8, 2021 |
CMII / CM Life Sciences II Inc. Class A / NOVARTIS PHARMA AG - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 1, 2021 |
Power of Attorney (included with the signature page of the Form S-1 filed on October 1, 2021).* S-1 1 fs12021somalogicinc.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 SOMALOGIC, INC. (Exact name of Registrant as specified in its charter) Delaware 8732 52-4298912 (State or other juri |
|
| September 24, 2021 |
CMII / CM Life Sciences II Inc. Class A / GAGNON SECURITIES LLC - SC 13G/A Passive Investment SC 13G/A 1 somalogic13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SomaLogic, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 83444K105 (CUSIP Number) September 1, 2021 (Date of Event Which Requires Filing of this Statement) Ch |
|
| September 15, 2021 |
CMII / CM Life Sciences II Inc. Class A / CMLS Holdings II LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 SomaLogic, Inc. (Name of Issuer) CMLS II Holdings LLC Eli Casdin and Keith Meister c/o Corvex Management LP 667 Madison Avenue New York, New York 10065 (212) 474-6745 (Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications) Common stoc |
|
| September 8, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the ?Form 8-K?). The following unaudited pro forma condensed combined balance sheet of the post-combination company as of June 30, 2021 and the unaudited pro forma condensed combined statements |
|
| September 8, 2021 |
Exhibit 21.1 SUBSIDIARIES OF SOMALOGIC, INC. Name of Subsidiary Jurisdiction 1. SomaLogic Operating Co., Inc. Delaware 2. SomaLogic Limited United Kingdom |
|
| September 8, 2021 |
SomaLogic, Inc. Condensed Consolidated Balance Sheets Exhibit 99.3 SomaLogic, Inc. Condensed Consolidated Balance Sheets (unaudited) (dollars in thousands, except for share and per share amounts) As of June 30, 2021 As of December 31, 2020 Assets Current assets: Cash and cash equivalents $ 47,138 $ 164,944 Investments 111,041 39,954 Accounts receivable, net 13,566 17,449 Inventory 7,662 7,020 Deferred costs of services 1,721 1,450 Prepaid expenses an |
|
| September 8, 2021 |
Exhibit 99.1 SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker ?SLGC? on the Nasdaq Stock Exchange ? SomaLogic to debut on Nasdaq as a leading publicly traded AI-data driven proteomics platform company ? Business combination results in approximately $630 million in gross cash proceeds to catalyze organic and inorganic growth initiatives ? Combined company to trade on Na |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 SOMALOGIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-40090 52-4298912 (State or other jurisdiction of incorporation) (Commission File |
|
| September 8, 2021 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of SomaLogic?s results of operations and financial condition should be read in conjunction with the information set forth in SomaLogic?s audited consolidated financial statements as of and for the years ended December 31, 2020 and 2019 and the unaudited condensed consolidated |
|
| September 8, 2021 |
Letter from Withum to the U.S. Securities and Exchange Commission dated September 8, 2021. Exhibit 16.1 September 8, 2021 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Ladies and Gentlemen: We have read SomaLogic, Inc.?s (formally known as CM Life Sciences II Inc.) statements included under Item 4.01(a) of its Form 8-K dated September 8, 2021. We agree with the statements concerning our Firm under Item 4.01(a), in which we were |
|
| September 1, 2021 |
Amended and Restated Bylaws of SomaLogic, Inc. Exhibit 3.2 Bylaws of SomaLogic, Inc. (a Delaware corporation) Table of Contents Page No. Article I ? Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II ? Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting. 1 2.5 Notice of Nominations for Election to the Board of Directors. 4 2. |
|
| September 1, 2021 |
Amended and Restated Registration Rights Agreement. Exhibit 10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of September 1, 2021, is made and entered into by and among CM Life Sciences II Inc., a Delaware corporation (the ?Company?), CMLS Holdings II LLC, a Delaware limited liability company (the ?Sponsor?), the undersigned parties listed on the signature p |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 SomaLogic, Inc. (Exact name of registrant as specified in its charter) Delaware 52-4298912 (State of incorporation or organization) (I.R.S. Employer Identification No.) 2945 W |
|
| September 1, 2021 |
Second Amended and Restated Certificate of Incorporation of SomaLogic, Inc. Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 09:30 AM 09/01/2021 FILED 09:30 AM 09/01/2021 SR 20213136834 - File Number 4454683 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CM LIFE SCIENCES II INC. CM Life Sciences II Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS F |
|
| September 1, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 CM Life Sciences II Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commissio |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 27, 2021 CM Life Sciences II, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or other jurisdiction of incorporation) (Commissi |
|
| August 27, 2021 |
425 1 ea146525-8kcmlife2.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 27, 2021 CM Life Sciences II, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40090 85-4298912 (State or ot |
|
| August 23, 2021 |
Filing pursuant to Rule 425 under the 425 1 ea146272-425cmlifesci.htm FINANCIAL UPDATE Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Filer: CM Life Sciences II, Inc. Filer’s Commission File Number: 001-40090 Subject Company: CM Life Sciences II, Inc. Date: August 23, 2021 SomaLogic Provides 2021 Financial Guidance Exceeding Initial Merger Combination Projections NEW YORK & BOULDER, Colo. (August 23, 2021) – |
|
| August 18, 2021 |
425 1 ea146086-425cmlifesci2.htm FORM 425 Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Filer: CM Life Sciences II Inc. Filer’s Commission File Number: 001-40090 Subject Company: CM Life Sciences II Inc. Date: August 18, 2021 FOR IMMEDIATE RELEASE SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies BOULDER, |
|
| August 16, 2021 |
Filing pursuant to Rule 425 under the 425 1 ea145871-425cmlifescience2.htm FORM 425 Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Filer: CM Life Sciences II Inc. Filer’s Commission File Number: 001-40090 Subject Company: CM Life Sciences II Inc. Date: August 16, 2021 FOR IMMEDIATE RELEASE SomaLogic Announces Registration Statement Declared Effective and Reports 176% Y/Y Second Quarter and 187% First Half of |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40090 CM LIFE SCIENCES |
|
| August 12, 2021 |
Filed Pursuant to Rule 424(b)(3) 424B3 1 f424b30821cmlifesciences2.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No.: 333-256127 PROXY STATEMENT/PROSPECTUS DATED AUGUST 12, 2021 CM LIFE SCIENCES II INC. c/o Corvex Management 667 Madison Avenue New York, New York Dear Stockholder of CM Life Sciences II Inc.: You are cordially invited to attend the special meeting of stockholders (“Special Meeting”) of CM Life Scienc |
|
| August 11, 2021 |
CM Life Sciences II Inc. 667 Madison Avenue New York, NY 10065 CM Life Sciences II Inc. 667 Madison Avenue New York, NY 10065 August 11, 2021 VIA EDGAR Division of Corporation Finance Office of Telecommunications Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: CM Life Sciences II Inc. Amendment No. 3 to Registration Statement on Form S-4 Filed July 22, 2021 File No. 333-256127 Ladies and Gentlemen: Pursuant to Rule 461 of the |
|
| August 5, 2021 |
August 5, 2021 United States Securities and Exchange Commission Office of Trade & Services Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Cara Wirth, Dietrich King CM Life Sciences II Inc. |
|
| August 5, 2021 |
As filed with the United States Securities and Exchange Commission on August 5, 2021. |
|
| July 22, 2021 |
Specimen Common Stock Certificate. Exhibit 4.1 NUMBER SHARES C- SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP SOMALOGIC, INC. COMMON STOCK THIS CERTIFIES THAT is the owner of fully paid and non-assessable shares of common stock, par value $0.0001 per share (the ?Common Stock?), of SomaLogic, Inc., a Delaware corporation (the ?Company?), transferable on the books of the Company in person or by duly authorized attorney upon surrender of |
|
| July 22, 2021 |
As filed with the United States Securities and Exchange Commission on July 21, 2021. As filed with the United States Securities and Exchange Commission on July 21, 2021. |
|
| July 22, 2021 |
Consent of Ted Meisel to be named as director Exhibit 99.7 CONSENT TO REFERENCE IN PROXY STATEMENT/ PROSPECTUS July 21, 2021 CM Life Sciences II Inc. 667 Madison Avenue New York, New York CM Life Sciences II Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, pursuant to Ru |
|
| July 22, 2021 |
Amendment to Employment Agreement dated June 28, 2021 between SomaLogic, Inc. and Melody Harris. Exhibit 10.20 SOMALOGIC, INC. FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT (?Amendment?) hereby amends that certain EMPLOYMENT AGREEMENT, entered into as of April 20, 2020 (the ?Prior Agreement?), by and between SomaLogic, Inc. (the ?Company?) and Melody Harris (the ?Employee? and, together with the Company, the ?Parties?). WHEREAS, the Parties entered into the Prior Agreement to p |
|
| July 22, 2021 |
Consent of Robert Barchi to be named as director Exhibit 99.5 CONSENT TO REFERENCE IN PROXY STATEMENT/ PROSPECTUS July 21, 2021 CM Life Sciences II Inc. 667 Madison Avenue New York, New York CM Life Sciences II Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, pursuant to Ru |
|
| July 22, 2021 |
Consent of Richard Post to be named as director Exhibit 99.8 CONSENT TO REFERENCE IN PROXY STATEMENT/ PROSPECTUS July 21, 2021 CM Life Sciences II Inc. 667 Madison Avenue New York, New York CM Life Sciences II Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, pursuant to Ru |
|
| July 22, 2021 |
Form of Preliminary Proxy Card. Exhibit 99.1 |
|
| July 22, 2021 |
Consent of Anne Margulies to be named as director Exhibit 99.6 CONSENT TO REFERENCE IN PROXY STATEMENT/ PROSPECTUS July 21, 2021 CM Life Sciences II Inc. 667 Madison Avenue New York, New York CM Life Sciences II Inc. (the ?Company?) is filing a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?). In connection therewith, I hereby consent, pursuant to Ru |
|
| July 22, 2021 |
Amendment to Employment Agreement dated June 28, 2021 between SomaLogic, Inc. and Stephen Williams. EX-10.19 6 fs42021a2ex10-19cmlife2.htm AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN SOMALOGIC, INC. AND STEPHEN WILLIAMS Exhibit 10.19 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of April 20, 2020 (the “Effective Date”), between Steve Williams (the “Employee”), and SomaLogic, Inc. (the “Company”). RECITALS A. Employee is currently employed by the Company as it |
